Moneycontrol PRO
you are here: HomeNewsOpinion

Corporate Corridor | Pharma has a tough climb to regain investor faith

Compliance-related issues with the US FDA just don’t seem to be going away any time soon. In India, a key threat is the government’s efforts to make drugs affordable, and what policy changes it adopts to fulfil that objective.

July 16, 2019 / 04:37 PM IST
Corporate Corridor | Pharma has a tough climb to regain investor faith

Will FY20 be the year when the Indian generic pharmaceutical sector regains its lost glory? Yes, you want to say, when you read news that Dr Reddy’s Laboratories has won a case that allows it to keep selling a key drug in the US market. The US Federal Appeals Court ruled that Dr Reddy’s generic version of Indivior’s Suboxone did not infringe two patents. The incremental financial implication of this ruling is not much because Dr Reddy’s is already selling...

  • PRO Panorama

    Moneycontrol Pro Panorama | Robinhood missed the mark on a bumper listing

    Jul 30, 2021 / 04:26 PM IST

    In today’s edition of Moneycontrol Pro Panorama:  Why Robinhood stumbled, the problem with IMF forecasts, the Immunity Tracker, Tech Mahindra’s growth appeal, Tactical Pick, the Indian startup rage, China pushes back on crypto and more  

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers